Here is the latest shareholding Pattern of LINK PHARMA. For more details, see the LINK PHARMA financial fact sheet and LINK PHARMA share price. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Jun-22 |
3
Sep-22 |
3
Dec-22 |
3
Mar-23 |
3
Jun-23 |
3
Sep-23 |
3
Dec-23 |
3
Mar-24 |
||
---|---|---|---|---|---|---|---|---|---|---|
Indian Promoters | % | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | |
Foreign Promoters | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Promoters | % | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | 51.49 | |
Mutual Funds | % | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Financial institution/Banks/Insurance | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Government | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
FII | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Other | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Institution | % | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
Bodies Corporate | % | 5.95 | 5.96 | 6.07 | 5.95 | 6.16 | 6.34 | 6.34 | 6.04 | |
Individuals | % | 38.96 | 38.97 | 38.98 | 39.15 | 38.39 | 38.24 | 37.05 | 37.71 | |
NRIs/OCBs | % | 2.16 | 2.04 | 2.05 | 2.06 | 2.07 | 2.07 | 2.07 | 2.11 | |
ADR/GDR | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Others | % | 1.42 | 1.52 | 1.39 | 1.33 | 1.87 | 1.84 | 3.03 | 2.63 | |
Total Non-Institution | % | 48.49 | 48.49 | 48.49 | 48.49 | 48.49 | 48.49 | 48.49 | 48.49 | |
Total Public | % | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | |
Grand Total | % | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
Pledged Promoter Holding | % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Subscriber Feature |
More Pharmaceuticals Company Shareholding Pattern: ZYDUS LIFESCIENCES CIPLA DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.